Результаты поиска

Abstracts from the 8th Drug Hypersensitivity Meeting (DHM)

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Etoricoxib Not approved 7 0.68 Celecoxib Labeled 4 0.39 Mefenamic acid Labeled 4 0.39 Ibuprofen Labeled 3 0.29 Meloxicam Labeled 2 0.19 Etodolac Labeled 1 0.10 Metamizole Not approved 1 0.10 Naproxen Labeled 1 0.10 Other drugs US FDA n (%) Allopurinol Labeled 202 19.65 Sulfasalazine Labeled 19 1.85 Esomeprazole … 0.39 Mefenamic acid | Labeled | 4 | 0.39 Ibuprofen | Labeled | 3 | 0.29 Meloxicam | Labeled | 2 | 0.19 Etodolac | Labeled | 1 | 0.10 Metamizole | Not approved | 1 | 0.10 Naproxen | Labeled | 1 | 0.10 Other drugs | US FDA | n | (%) Allopurinol | Labeled | 202 | 19.65 Sulfasalazine | Labeled | 19 | 1.85 Esomeprazole …

Global first-in-class drugs approved in 2023-2024: Breakthroughs and insights.

First-in-class (FIC) drugs are considered the main drivers of new drug discovery and have novel targets and mechanisms. The proportion of FIC drugs among new drugs provides fundamental guidance for both academic and pharmaceutical research. From a global perspective, 81 FIC drugs were approved in 2023 and 2024. Among them, small-molecule drugs account for a greater percentage (51.9%), illustrating the discovery of new chemical entities. Macromolecule drugs (48.1%), which mainly consist of antibody analogs, represent a growing trend as new biotechnology techniques have emerged. In terms of FIC

Совпадение в полном тексте источника
… A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole Nat. Rev. Drug Discov. 2 2003 132 139 12563304 10.1038/nrd1010 5 Keam S.J. Zolbetuximab: First Approval Drugs 84 2024 977 983 38967717 10.1007/s40265-024-02056-x 6 Nakayama I. Qi C. Chen Y. …

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

The management of chronic myeloid leukemia with BCR-ABL1 tyrosine kinase inhibitors has evolved chronic myeloid leukemia into a chronic, manageable disease. A patient-centered approach is important for the appropriate management of chronic myeloid leukemia and optimization of long-term treatment outcomes. The pharmacist plays a key role in treatment selection, monitoring drug-drug interactions, identification and management of adverse events, and educating patients on adherence. The combination of tyrosine kinase inhibitors with unique safety profiles and individual patients with unique medica

Совпадение в полном тексте источника
… The prescribing information for nilotinib recommends use of H2 antagonists 10 h before or 2 h after nilotinib 3 ; however, no significant changes in the nilotinib Cmax were observed in a small study of 22 patients taking nilotinib concomitantly with the PPI esomeprazole. 6 Prescribing information for …

Clinical challenges in the management of osteoporosis.

While knowledge regarding the diagnosis and treatment of osteoporosis has expanded dramatically over the last few years, gaps in knowledge still exist with guidance lacking on the appropriate management of several common clinical scenarios. This article uses fictional clinical scenarios to help answer three challenging questions commonly encountered in clinical practice. The first clinical challenge is when to initiate drug therapy in a patient with low bone density. It is estimated that 34 million America have low bone density and are at a higher risk for low trauma fractures. Limitations of

Совпадение в полном тексте источника
… Her past medical history is significant only for hypertension and mild gastroesophageal reflux disease for which she takes hydrochlorothiazide and esomeprazole orally once daily. Her family history is significant for a mother who had a hip fracture at the age of 85 years. …

UEG Week 2017 Oral Presentations

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.

Tyrosine kinase inhibitors (TKIs) are anti-cancer drugs that target tyrosine kinases, enzymes that are involved in multiple cellular processes. Currently, multiple oral TKIs have been introduced in the treatment of solid tumours, all administered in a fixed dose, although large interpatient pharmacokinetic (PK) variability is described. For imatinib, sunitinib and pazopanib exposure-treatment outcome (efficacy and toxicity) relationships have been established and therapeutic windows have been defined, therefore dose optimization based on the measured blood concentration, called therapeutic dru

Совпадение в полном тексте источника
… Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Cancer Chemother Pharmacol. 2013;71(6):1635‐1643. 10.1007/s00280-013-2164-3 Epub 2013 May 1. 135. Groenland SL, Mathijssen RHJ, Beijnen JH, Huitema ADR, Steeghs N. …

Targeting strategies for bone diseases: signaling pathways and clinical studies.

Since the proposal of Paul Ehrlich's magic bullet concept over 100 years ago, tremendous advances have occurred in targeted therapy. From the initial selective antibody, antitoxin to targeted drug delivery that emerged in the past decades, more precise therapeutic efficacy is realized in specific pathological sites of clinical diseases. As a highly pyknotic mineralized tissue with lessened blood flow, bone is characterized by a complex remodeling and homeostatic regulation mechanism, which makes drug therapy for skeletal diseases more challenging than other tissues. Bone-targeted therapy has b

15th Конгресс Европейской ассоциации клинической фармакологии и терапии (ЕАКПТ)

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Всемирный конгресс молекулярного воображения 2022.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer.

In cancer patients, thrombocytopenia can result from bone marrow infiltration or from anticancer medications and represents an important limitation for the use of antithrombotic treatments, including anticoagulant, antiplatelet, and fibrinolytic agents. These drugs are often required for prevention or treatment of cancer-associated thrombosis or for cardioembolic prevention in atrial fibrillation in an increasingly older cancer population. Data indicate that cancer remains an independent risk factor for thrombosis even in case of thrombocytopenia, since mild-to-moderate thrombocytopenia does n

Совпадение в полном тексте источника
… Among patients receiving clopidogrel, omeprazole and esomeprazole are not recommended, and pantoprazole must be considered instead. Level 1, grade A d. Clinically relevant DDIs should be always considered, especially for clopidogrel, ticagrelor, warfarin, and dabigatran (see Suppl. Table S1 ). …

Неделя ГЭЭ 2017 Презентации на плакате

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

2020 ACVIM Forum On Demand Research Abstract Program.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Second-Generation Antimitotics in Cancer Clinical Trials.

Mitosis represents a promising target to block cancer cell proliferation. Classical antimitotics, mainly microtubule-targeting agents (MTAs), such as taxanes and vinca alkaloids, are amongst the most successful anticancer drugs. By disrupting microtubules, they activate the spindle assembly checkpoint (SAC), which induces a prolonged delay in mitosis, expected to induce cell death. However, resistance, toxicity, and slippage limit the MTA's effectiveness. With the desire to overcome some of the MTA's limitations, mitotic and SAC components have attracted great interest as promising microtubule

Совпадение в полном тексте источника
… , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 143 , 144 , 144 , 145 , 146 , 147 , 148 ] Combination with Pazopanib, Bortezomib, Docetaxel, Irinotecan, Temozolomide, Daunorubicin, Idarubicin, Cytarabine, Rituximab, Vincristine, Paclitaxel, Oxaliplatin, Leucovorin, Fluorouracil, Esomeprazole …

Abstracts of the 36th Annual Meeting of the Society of General Internal Medicine. April 24-27, 2013. Denver, Colorado, USA.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Disorders of the Gastrointestinal System

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

UEG Week 2015 Poster Presentations

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Неделя ГЭЭ 2018 Презентации на плакате

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Inpatient Medicine

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

62nd Annual Conference of the Indian Society of Gastroenterology, February 10th - 13th, 2022, Pune.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

50th ESCP Symposium on Clinical Pharmacy, Polypharmacy and ageing - highly individualized, interprofessional, person-centered care : 19–21 October 2022, Prague, Czech Republic

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.